Skip to content

US · AGMB · BIOTECHNOLOGY

AgomAb Therapeutics N.V. American Depositary Shares (AGMB) intrinsic value and stock valuation

$5.45as of 2026-11-21 · Mkt cap 714.1M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AgomAb Therapeutics N.V. American Depositary Shares DCF and intrinsic value

InvestorsCraft values AGMB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AGMB’s statements →

AgomAb Therapeutics N.V. American Depositary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Antwerp, VL 2600 agomab.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-60.08M
20222025
Free cash flow
-$-51.74M
20252025
Total equity
$130.9M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-59.27M-$-48.02M-$-31.19M-$-22.63M
Net income-$-60.08M-$-46.27M-$-11.39M-$-8.14M
EPSd-$-1.23M-$-1.28M-$-314.29K-$-224.61K
Operating cash flow-$-51.74M———
Capital expenditure-$0.00———
Free cash flow-$-51.74M———
Total assets$153.7M———
Total debt$1.25M———
Net debt-$-85.16M———
Total equity$130.9M———
Cash and short-term investments$116.5M———
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$210K$0.00$0.00$0.00
Gross profit-$-210K$0.00$0.00$0.00
Research and development expenses$48.9M$39.3M$26.3M$19.4M
Selling, general and administrative expenses$12.6M$9.82M$6M$4.49M
Other expenses-$-2.17M-$-1.11M-$-1.12M-$-1.28M
Operating expenses$59.3M$48M$31.2M$22.6M
Cost and expenses$59.3M$48M$31.2M$22.6M
Interest income$1.55M$1.22M$240K$70K
Interest expense$70K$70K$30K$40K
Depreciation and amortization$220K$310K$100K$20K
Ebitda-$-62.27M-$-45.88M-$-11.88M-$-10.74M
Operating income-$-59.27M-$-48.02M-$-31.19M-$-22.63M
Total other income/expenses, net-$-3.27M$1.76M$19.2M$11.8M
Income before tax-$-62.55M-$-46.26M-$-12.01M-$-10.81M
Income tax expense-$-490K$0.00-$-620K-$-2.66M
Net income-$-60.08M-$-46.27M-$-11.39M-$-8.14M
Weighted average shares outstanding$48.7M$36.2M$36.2M$36.2M
Weighted average diluted shares outstanding$48.7M$36.2M$36.2M$36.2M
Balance sheet
2025
Cash and short-term investments$116.5M
Net receivables$4.78M
Inventory$0.00
Total current assets$121.2M
Property, plant and equipment, net$1.59M
Goodwill and intangible assets$33.7M
Long-term investments$10K
Total non-current assets$32.5M
Total assets$153.7M
Accounts payable$7.63M
Short-term debt$250K
Deferred revenue$1.46M
Total current liabilities$18.6M
Long-term debt$1M
Deferred revenue, non-current$0.00
Total non-current liabilities$4.21M
Capital lease obligations$1.25M
Total liabilities$22.8M
Common stock$223.1M
Retained earnings-$-181.71M
Accumulated other comprehensive income (loss)-$-970K
Total equity$130.9M
Total investments$30.1M
Total debt$1.25M
Net debt-$-85.16M
Cash flow statement
2025
Net income-$-62.55M
Depreciation and amortization$220K
Stock-based compensation$5.36M
Change in working capital$410K
Accounts receivable$0.00
Inventory$0.00
Accounts payable$0.00
Net cash provided by operating activities-$-51.74M
Investments in property, plant and equipment-$0.00
Acquisitions, net-$-3M
Net cash used for investing activities-$-33M
Common stock issued$0.00
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities-$-340K
Net change in cash-$-85.04M
Cash at end of period$86.4M
Operating cash flow-$-51.74M
Capital expenditure-$0.00
Free cash flow-$-51.74M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AgomAb Therapeutics N.V. American Depositary Shares

        AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.

        CEO
        Tim Knotnerus
        Employees
        62
        Beta
        1.73

        Explore

        Frequently asked questions

        What is the intrinsic value of AgomAb Therapeutics N.V. American Depositary Shares (AGMB)?

        InvestorsCraft does not currently publish an intrinsic value for AGMB. How the IC value is calculated.

        Is AGMB undervalued?

        InvestorsCraft does not publish an undervaluation signal for AGMB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.